For the second consecutive year, Roswell Park Cancer Institute has been named a Guardian of Excellence Award winner by Press Ganey, a prestigious designation that recognizes sustained high performance in patient experience.

NHL.com released a story yesterday highlighting a mannequin challenge video taken while the Buffalo Sabres team was visiting with patients at Roswell Park Cancer Institute. The Sabres team split into groups to take two separate videos which were shared on Roswell Park’s Facebook page, asking followers “who did it better?”

BUFFALO, N.Y. (Dec. 8, 2016) – Roswell Park Cancer Institute has again been recognized as an Optum® Center of Excellence (COE) in the areas of adult and pediatric blood and marrow transplantation (BMT).

Just in time for the holiday season, Roswell Park Cancer Institute, in collaboration with Tony Walker & Co, has released a limited-edition necklace that carries powerful affirmations close to the heart of those facing, or who have faced, a cancer diagnosis. The “Roswell Strong” necklace features a four-sided bar pendant inscribed with meaningful messages to inspire and empower: Cancer Warrior, Determined, Brave and Blessed.

Roswell Park Cancer Institute has released The Paint Box Project’s 2016 Holiday Line, featuring 13 new designs for customizable holiday cards, gifts, packaging and tableware. As always, pediatric cancer patients and their families design all of the artwork for the items.

Roswell Park Cancer Institute’s annual Tree of Hope lighting ceremony will be held on Friday, Dec. 9, from 4:30 to 6:30 p.m. in Kaminski Park and Gardens on the Roswell Park campus.

Roswell Park Cancer Institute physicians and researchers will be among the scientific leaders offering new insights into the causes and treatment of blood disorders during the 58th annual meeting of the American Society of Hematology (ASH) December 3 – 6 in San Diego, California.

A new clinical study underway at Roswell Park Comprehensive Cancer Center is the first to test the combination of the immunotherapy pembrolizumab with two other drugs as treatment for recurrent epithelial ovarian cancer, and is also the first ovarian cancer clinical trial to incorporate analysis of patients’ microbiomes — the bacteria present in the human gut and other organs.